Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19) coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be hospitalized, should receive at least prophylactic dose anticoagulation. However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence.

新型冠状病毒病2019（COVID-19）的特征是静脉血栓栓塞，透析导管堵塞，体外膜氧合（ECMO）设备的回路血栓形成，急性肢体缺血和孤立的中风，所有这些都面临预防性甚至治疗性抗凝的情况凝血病。目前看来，已经确定已经有足够病患可以住院的COVID-19患者应接受至少预防剂量的抗凝治疗。然而，某些住院患者是否应将剂量增加到中等剂量？是否应考虑在无可测量的血栓栓塞事件的情况下进行全剂量抗凝治疗，应如何监测抗凝治疗？患者应在出院后接受抗凝治疗，用什么药物治疗并持续多长时间？哪些血栓问题与用于治疗该凝血病的各种药物有关？抗磷脂抗体是该综合征的一部分吗？孤立性缺血性中风和肢体缺血在该疾病中的意义何在？与这种疾病的其他临床和实验室特征有何关系？本文的目的是探讨这些问题并根据当前证据解释可用的数据。